Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
173
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,659.15 | 317.64 | -1.22% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,869.37 | 19.97 | -0.51% |